FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss — Live Feedhttps://www.live-feeds.com/feed/fda-warns-glp-1-drugs-may-pose-risk-of-rare-condition-that-causes-vision-lossContinuously updated, source-cited coverage. FDA Orders New Eye Risk Warnings for GLP-1 Drugshttps://www.live-feeds.com/feed/fda-warns-glp-1-drugs-may-pose-risk-of-rare-condition-that-causes-vision-losshttps://www.live-feeds.com/feed/fda-warns-glp-1-drugs-may-pose-risk-of-rare-condition-that-causes-vision-loss#u199275Fri, 13 Nov 2026 19:25:16 +0000United States regulators ordered new warning labels on GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Zepbound. The updated labels must highlight a possible risk of a rare condition that causes permanent vision loss and potential blindness. Drug manufacturers are now required to add these safety warnings regarding the rare eye condition. The directive follows mounting regulatory review of the popular diabetes and weight loss treatments. Patients currently taking these medications face new safety communications regarding the vision risks, though the specific condition remain